MedTrace Logo

Personalizing Immune Checkpoint Inhibitor Therapy

NCT03409341 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-09-24

No results posted yet for this study

Summary

This prospective, observational study will evaluate whether vitro testing of tumor tissue and white blood cells from patients with lung cancer who are being treated with immune checkpoint inhibitors and other standard of care approaches, predicts clinical response to these agents.

Conditions

  • Lung Cancer Stage IV

Interventions

OTHER

Blood and tumor tissue analysis, Clinical response.

DNA sequencing and functional testing of peripheral blood mononuclear cells. DNA and RNA sequencing and immune cell analysis of tumor. Clinical response at 12 months.

Sponsors & Collaborators

  • Holy Cross Hospital, Maryland

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2020-01-08
Completion
2020-09-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03409341 on ClinicalTrials.gov